In this Issue:
Proton therapy versus CyberKnife
RALP versus open RRP
ADT plus radiotherapy for intermediate-risk prostate cancer
Smoking, DNA methylation and prostate cancer outcomes
Tasquinimod in men with mCRPC
Long-term QoL in localised prostate cancer survivors
Phase I dose-escalation study of apatorsen (OGX-427)
Statins and clinical outcomes in prostate cancer
Prostate inflammation association with prostate cancer risk
Is PIVOT generalisable? – OS with localised prostate cancer
Please login below to download this issue (PDF)